retatrutide phase 3 2025 triple agonist glp-1 gip glucagon (Eli Lilly's GLP-1/GIP/Glucagon receptor agonist) just delivered the most impressive obesity + osteoarthritis data we've ever seen in the TRIUMPH-4 trial: retatrutide triple agonist glp-1 gip
Description
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report
75 A comparative study conducted in China over 24 weeks evaluated the treatment of MASLD and T2DM in patients not receiving additional glucose control medications
Pan HC, Chen JY, Chen HY, Yeh FY, Sun CY, Huang TT
